KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Gains from Sales and Divestitures (2023 - 2025)

Opko Health (OPK) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $850146.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 54.66% year-over-year to $850146.0, compared with a TTM value of $850146.0 through Dec 2025, up 54.66%, and an annual FY2025 reading of $850146.0, up 54.66% over the prior year.
  • Gains from Sales and Divestitures was $850146.0 for Q4 2025 at Opko Health, up from $549687.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $850146.0 in Q4 2025 and bottomed at $549680.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 3 years is $649837.7, with a median of $549687.0 recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures grew 0.0% in 2024, then soared 54.66% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $549680.0 in 2023, then increased by 0.0% to $549687.0 in 2024, then skyrocketed by 54.66% to $850146.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for OPK at $850146.0 in Q4 2025, $549687.0 in Q4 2024, and $549680.0 in Q4 2023.